Send the following on WhatsApp
Continue to ChatEisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma https://medicalnewsmiami.com/eisai-and-merck-co-inc-present-results-from-phase-3-leap-002-trial-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocel/